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ABSTRACT 
 
This study is a hospital based, case controlled, cross-sectional 
study, carried out during the period from July 2003 till January 2005 in 
ElShaab and Khartoum Teaching Hospitals, to assess the prevalence of 
Antiphospholipid antibodies (APLAs) in ischaemic brain disease (IBD) 
patients and to find out their special features. 
160 individuals were studied; 89 with IBD (48 females and 41 
males), 35 with other diseases (13 females, 22 males), 36 healthy 
control (18 females, 18 males). 
Patients were studied using a simple direct, standardized 
questionnaire including, history, physical examination and 
investigations. 
All individual were tested for APLAs, IBD patients were 
examined by CT brain, ESR and platelets, lipid profile and blood 
sugars.  
Antinuclear factor (ANF) was done in 24 patients, anti double 
stranded DNA in 18, partial thrombo blastin time (PTT) in 16 and 
VDRL in 14 patients. Echocardiography was done in eight patients, 
echocardiography and carotid Doppler’s in six patients. Follow-up CT 
scan brain six weeks following stroke was done in four APLAs +ve 
patients.  
APLAs +ve patients with IBD showed a female : males ratio of       
2 : 1.5 and increased incidence in the age group 20-29 years. 
  
APLAs +ve patients at presentation tend to have more headache and 
fits but have less disturbance of consciousness, speech disturbance or motor 
weakness compared to those who were APLA –ve. They were also found to 
have more frequent history of DVT, migraine and abortion. 
APLAs were found to be strongly associated with elevated ESR 
and low platelets, +ve VDRL, carotid stenosis, ANF and prolonged 
PTT.    
Follow-up CT brain six weeks following stroke was done in four 
patients and found to return to normal in three of them. 
The study demonstrated higher local incidence of APLAs in IBD 
than that reported worldwide, and they tends to occur more commonly 
in young females with IBD, suggesting a possible causal relationship. 
The study also suggested a better prognosis in stroke patients for 
motor weakness and CT changes.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 ﻣﻠﺨـــﺺ اﻟﺪراﺳــــﺔ
  
ﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺍﻻﻗﺘﻄﺎﻋﻴﺔ ﺍﳌﻘﺎﺭﻧﺔ ﺍﺭﺗﻜﺰﺕ ﻋﻠﻰ ﺍﻟﻌﻤﻞ ﺍﻟﺼﺤﻲ ﲟﺴﺘﺸﻔﻴﺎﺕ ﺍﳋﺮﻃﻮﻡ ﻭ 
ﻗﹸﺼﺪ ﻣﻦ ﺍﻟﺪﺭﺍﺳﺔ ﻟﺘﻘﻴﻴﻢ ﺣﺪﺍﺛﺔ . ﻡ5002ﻡ ﻭﺣﱴ ﻳﻨﺎﻳﺮ 3002ﺍﻟﺸﻌﺐ ﺃﺛﻨﺎﺀ ﺍﻟﻔﺘﺮﺓ ﻣﻦ ﻳﻮﻟﻴﻮ 
  (.ﻕ. ﺩ. ﻡ)ﺭﻳﺔ ﻣﻀﺎﺩﺍﺕ ﺍﻟﺪﻫﻮﻥ ﺍﻟﻔﺴﻔﻮ
ﰲ ﻣﺮﺿﻰ ﺍﻟﺴﻜﺘﺔ ﺍﻟﺪﻣﺎﻏﻴﺔ ﺍﻟﻨﺎﲡﺔ ﻋﻦ ﻧﻘﺺ ﺍﻟﺘﺮﻭﻳﺔ ﺍﻟﺪﻣﻮﻳﺔ ﺍﻟﺪﻣﺎﻏﻴﺔ ﻭﻻﻛﺘﺸﺎﻑ ﺧﺼﺎﺋﺼﻬﻢ 
  .ﺍﳌﻤﻴﺰﺓ
ﻣﺎﺋﺔ ﻭﺳﺘﻮﻥ ﻣﺮﻳﻀﺎﹰ ﲤﺖ ﺩﺭﺍﺳﺘﻬﻢ ﰲ ﻫﺬﻩ ﺍﻟﻔﺘﺮﺓ ﻭﻛﺎﻥ ﻣﻨﻬﻢ ﺗﺴﻌﺔ ﻭﲦﺎﻧﻮﻥ ﻣﺮﻳﻀﺎﹰ ﻳﻌﺎﻧﻮﻥ ﻣﻦ 
ﻭﺛﻼﺛﻮﻥ ﻛﺎﻧﻮﺍ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﲬﺴﺔ . ﻧﻘﺺ ﺗﺮﻭﻳﺔ ﺩﻣﺎﻏﻲ ﻣﻨﻬﻢ ﲦﺎﱐ ﻭﺃﺭﺑﻌﲔ ﺍﻣﺮﺃﺓ ﻭﻭﺍﺣﺪ ﻭﺃﺭﺑﻌﲔ ﺭﺟﻼﹰ
ﺳﺘﺔ ﻭﺛﻼﺛﻮﻥ ﻛﺎﻧﻮﺍ ﻣﻘﺎﺭﻧﲔ . ﺍﻣﺮﺍﺽ ﺃﺧﺮﻯ ﻭﻛﺎﻥ ﻣﻦ ﻫﺆﻻﺀ ﺛﻼﺙ ﻋﺸﺮﺓ ﺍﻣﺮﺃﺓ ﻭﺍﺛﻨﺎﻥ ﻭﻋﺸﺮﻭﻥ ﺭﺟﻼﹰ
  .ﺃﺻﺤﺎﺀ ﻣﻨﻬﻢ ﲦﺎﱐ ﻋﺸﺮﺓ ﺇﻣﺮﺃﺓ ﻭﲦﺎﱐ ﻋﺸﺮ ﺭﺟﻼﹰ
ﰎ ﻭﺿﻊ ﺍﺳﺘﺒﻴﺎﻥ ﳕﻮﺫﺟﻲ ﺑﺴﻴﻂ ﻭﻣﺒﺎﺷﺮ ﺗﻀﻤﻦ ﺗﺎﺭﻳﺦ ﺍﳌﺮﺽ ﻭﺍﻟﻜﺸﻒ ﺍﻟﺴﺮﻳﺮﻱ ﻭﺍﻟﻔﺤﻮﺹ 
  .ﺍﳌﺨﱪﻳﺔ
ﺔ ﰎ ﻓﺤﺼﻬﻢ ﲟﻀﺎﺩﺍﺕ ﺍﻟﺪﻫﻮﻥ ﺍﻟﻔﺴﻔﻮﺭﻳﺔ ، ﻣﻌﺪﻝ ﺗﺮﺳﺐ ﺍﻟﻜﺮﻭﻳﺎﺕ ﺍﳊﻤﺮﺍﺀ ، ﻛﻞ ﺃﻓﺮﺍﺩ ﺍﻟﻌﻴﻨ
  .ﻋﺪﺩ ﺍﻟﺼﻔﺎﺋﺢ ﺍﻟﺪﻣﻮﻳﺔ ، ﻣﻌﺪﻝ ﺍﻟﺪﻫﻮﻥ ﻭﺍﻟﺴﻜﺮ ﺑﺎﻟﺪﻡ
ﺃﺟﺮﻱ ﻓﺤﺺ ﺍﻟﻌﺎﻣﻞ ﺍﳌﻀﺎﺩ ﻟﻠﻨﻮﻱ . ﻣﺮﺿﻰ ﺍﻟﺴﻜﺘﺔ ﺍﻟﺪﻣﺎﻏﻴﺔ ﻓﺤﺼﻮﺍ ﺑﺎﻟﺘﺼﻮﻳﺮ ﺍﻟﻄﺒﻘﻲ ﻟﻠﺪﻣﺎﻍ
ﻴﺔ ﻋﺸﺮ ﻣﺮﻳﻀﺎﹰ ، ﻭﻓﺤﺺ ﺯﻣﻦ ﻷﺭﺑﻌﺔ ﻭﻋﺸﺮﻳﻦ ﻣﺮﻳﻀﺎﹰ ، ﻭﻓﺤﺺ ﻣﻀﺎﺩﺍﺕ ﺍﳊﻤﺾ ﺍﻟﻨﻮﻭﻱ ﺍﳌﺰﺩﻭﺝ ﻟﺜﻤﺎﻧ
  .ﺍﻟﺜﺮﻭﻣﺒﻮﺑﻼﺳﺘﲔ ﻟﺴﺘﺔ ﻋﺸﺮ ، ﻭﻓﺤﺺ ﺍﻟﺰﻫﺮﻱ ﻷﺭﺑﻌﺔ ﻋﺸﺮ
ﰎ ﺗﺼﻮﻳﺮ ﺍﻟﺸﺮﺍﻳﲔ ﺍﻟﺴﺒﺎﺗﻴﺔ ﺑﺎﻟﺪﻭﺑﻠﺮ ﰲ . ﰎ ﻓﺤﺺ ﺍﻟﻘﻠﺐ ﺑﺎﳌﻮﺟﺎﺕ ﻓﻮﻕ ﺍﻟﺴﻤﻌﻴﺔ ﰲ ﲦﺎﻧﻴﺔ ﻣﺮﺿﻰ
  .ﻑ. ﺩ. ﻛﺮﺭ ﺍﻟﺘﺼﻮﻳﺮ ﺍﻟﻄﺒﻘﻲ ﻟﻠﺪﻣﺎﻍ ﺑﻌﺪ ﺳﺘﺔ ﺃﺳﺎﺑﻴﻊ ﰲ ﺃﺭﺑﻊ ﻣﺮﺿﻰ ﻛﺎﻧﻮﺍ ﻣﻮﺟﺒﲔ ﻟـ ﻡ. ﺳﺘﺔ ﻣﺮﺿﻰ
ﻧﺴﺒﺔ ﺇﻧﺎﺙ ﻟﻠﺬﻛﻮﺭ ﺗﺴﺎﻭﻱ               . ﻑ. ﺩ. ﻬﺮ ﻣﺮﺿﻰ ﺍﻟﺴﻜﺘﺔ ﺍﻟﺪﻣﺎﻏﻴﺔ ﺍﳌﻮﺟﺒﲔ ﻟـ ﻡﺃﻇ
ﻛﺎﻥ ﻫﺆﻻﺀ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺻﺪﺍﻉ .  ﺳﻨﺔ92-02ﻭﺯﻳﺎﺩﺓ ﻣﻌﺪﻝ ﺍﻻﺻﺎﺑﺔ ﰲ ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺮﻳﺔ ﺑﲔ ½  1 :  2
ﻭﻧﻮﺑﺎﺕ ﺍﺧﻨﻼﺟﻴﺔ ﻭﻟﻜﻨﻬﻢ ﻛﺎﻧﻮﺍ ﺃﻗﻞ ﻣﻌﺎﻧﺎﺓ ﻣﻦ ﺍﺿﻄﺮﺍﺑﺎﺕ ﺍﻟﻮﻋﻲ ﻭﺍﳌﻨﻄﻖ ﻭﺍﻟﻀﻌﻒ ﺍﳊﺮﻛﻲ ﻣﻘﺎﺭﻧﺔ 
ﻛﺎﻧﻮﺍ ﺃﻳﻀﺎﹰ ﺃﻛﺜﺮ ﻣﻌﺎﻧﺎﺓ ﻣﻦ ﺍﻟﺸﻘﻴﻘﺔ ﻭﺍﻻﺟﻬﺎﺽ ﻭﲣﺜﺮ ﺍﻷﻭﺭﺩﺓ ﰲ . ﻑ. ﺩ. ﺮﺻﻔﺎﺋﻬﻢ ﺍﻟﺴﺎﻟﺒﲔ ﻟـ ﻡﺑ
  . ﺍﻟﺘﺎﺭﻳﺦ ﺍﳌﺎﺿﻲ
  
ﻣﺮﺗﺒﻄﺔ ﺑﻘﻮﺓ ﺑﺎﺭﺗﻔﺎﻉ ﻣﻌﺪﻝ ﺗﺮﺳﺐ ﺍﻟﻜﺮﻭﻳﺎﺕ ﺍﳊﻤﺮﺍﺀ ، ﻧﻘﺺ ﺍﻟﺼﻔﺎﺋﺢ . ﻑ. ﺩ. ﻭﺟﺪ ﺃﻥ ﻡ
 ﻟﻠﻨﻮﻯ ﻭﻃﻮﻝ ﺯﻣﻦ ﺍﻟﺪﻣﻮﻳﺔ ، ﺍﳚﺎﺏ ﻓﺤﺺ ﺍﻟﺰﻫﺮﻱ ، ﺗﻀﻴﻴﻖ ﺍﻟﺸﺮﻳﺎﻥ ﺍﻟﺴﺒﺎﰐ ، ﺍﳚﺎﺏ ﺍﻟﻌﺎﻣﻞ ﺍﳌﻀﺎﺩ
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ﺍﻟﻔﺤﺺ ﺍﻟﻄﺒﻘﻲ ﻟﻠﺪﻣﺎﻍ ﺃﻭﺿﺢ ﺍﻟﻌﻮﺩﺓ ﻟﻠﻮﺿﻊ ﺍﻟﻄﺒﻴﻌﻲ ﻋﻨﺪ ﺇﻋﺎﺩﺗﻪ ﺑﻌﺪ ﺳﺘﺔ ﺃﺳﺎﺑﻴﻊ ﰲ ﺛﻼﺛﺔ ﻣﻦ 
  . ﻑ. ﺩ. ﺃﺭﺑﻌﺔ ﻣﺮﺿﻰ ﻣﺼﺎﺑﲔ ﺑﺎﻟﺴﻜﺘﺔ ﺍﻟﺪﻣﺎﻏﻴﺔ ﻭﻣﻮﺟﺒﲔ ﻟـ ﻡ
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INTRODUCTION 
   Most of the early work leading to the detailed description of APS was 
carried out in the early 1980s by Dr.Graham Hughes and his colleagues 
while studying lupus.It became clear that some patients had a tendency to 
form blood clots in arteries and veins.this clotting was associated with a 
particular antibody which attacks phospholipids , 
Hence  the term antiphospholipid antibodies. 1 
Definition: 
Antiphospholipid syndrome(APS) is a disorder characterized by 
recurrent arterial or venous thrombosis, recurrent fetal loss,and autoimmune 
thrombocytopenia associated with the presence of antibodies against the 
cellular component phospholipids. 2   
Types: 
1. Primary APS; 
Not associated with systemic lupus or other autoimmune disease.  
2. Secondary APS; 
  Associated commonly with systemic lupus erythromatosis. 
Occurrence: 
It can affect a number of different organs in the body. All age groups 
can be affected; from infants to elderly. However, the majority of people 
with APS are aged between 20 and 50 years. 
The female to male ratio is 2 : 1. 
 
 
 
 
  
Clinical features: 
A. Pregnancy loss: 
Obstetric complications include recurrent fetal loss, often but not 
always in the late second or third trimester, severe pre-eclampsia,premature 
delivery;chorea gravidarum; intrauterine growth retardation or postpartum 
syndrome manifested by pleuropericarditis and fever. 
 
B. Thrombosis: 
All venous and arterial systems can be involved; commonly DVT  and  
strokes. 
  
C. Other  features: 
      Migraine, haemolytic anaemia, livedo-reticularis and thrombocytopenia. 
Antiphospholipid antibodies are an extremely heterogenous group                       
of antibodies directed against a variety of antigenic determinants  
platelets;coagulation proteins.and endothelial cells. Cerebral ischemia 
associated with apl is the most common arterial manifestation, However, the 
importance of apl as a cardiovascular risk factor is controversial. In many 
studies apl is associated with an increased risk for incidence and                        
recurrence of cerebral ischaemia; myocardial infarction; and venous 
thrombosis. Intracardiac thrombus has been reported .Regardless of age; 
patients with cerebral ischeamia often have other risk factors for 
cerebrovascular disease.APL may act in concert with other vascular risk 
factors that damage endothelial cells. A variety of cardiac valvular  lesions 
have been associated with apl; and cardiac emboli are a possible cause of 
cerebrovascular symptoms.  3 
    
  
Situations in which antiphospholipid  antibodies may be detected; Infections; 
Syphilis; malaria; H.I.V; Hepatitis C . 
Rheumatic and collagen vascular disease; S.L.E; systemic 
sclerosis;rheumatoid arthritis ; temporal arteritis; psoriatic arthorathy; 
sjogren  syndrome. 
Thrombatic disease: 
Venous thromboembolic disease; peripheral arterial occlusion; 
ischeamic heart disease; after coronary bypass graft surgery; valvular heart 
disease; pulmonary hypertension. 
Disorders of the nervous system and eye: 
Thrombotic stroke; transient ischemic attaks; sagittal sinus 
thrombosis; ischemic optic atrophy; multi-infarct dementia; chorea; guillian 
barre syndrome. 
Drugs: 
Phenothiazines.procainamide,hydralazine;phenytoin;quinidine. 
Miscellaneous:                                                            
Autoimmune thrombocytopenia and haemolytic anaemia;Behcet 
syndrome; sickle cell anaemia, intravenous drug abuse. 
The diagnosis of antiphospholipid antibody syndrome requires the 
antiphospholipid  antibody panel, lupus anticoagulant, anticardiolipin 
antibody on two separate occasions, at least 6 weeks a part, in the presence 
of thrombosis, thrombocytopenia or recurrent miscarriage. 
 
 
 
 
 
  
LITERATURE  REVIEW 
  
Antibodies    to   phospholipids     were    probably   first   described   
by   Wasserman    in    1906, who   had   developed   a laboratory   assay   for   
detection    of    syphilis, and   later by   Pangborn    in   1941, whose   
laboratory    assays    for   syphilis    utilized    a prepared    extract   of   
bovine   heart   muscle   which   is   rich   in   phospholipids   that   he   
called   cardolipin4.  
During   the    Second World War, laboratory    assays   for   syphilis   
were   being   performed   on   military   and    non-military   personnel; 
doctors   discovered   a number    of   people   with   positive   syphilis    test   
results, but   with   no    clinical    evidence   of   disease. In   follow –up   
studies   of   false positive   patients, it was    found    that   they   could be    
divided   into   two   groups, transient    false positive   (usually   due  to  
infection)   and   long   term   false  positive, where  there  was   a high  
prevalence   of   autoimmune   disorders   including   systemic  lupus   
erythermatosus  (LE)   . This   was   the   first   hint   that   there   was   an   
association   between   unusual   antibodies   (which   cause   a false   
positive   syphilis   test) and   autoimmune   disease.  4  
In   1952, Conley    and   Hartmann    reported    two   LE     patients   
with   bleeding   disorders   and    a false    positive   syphilis    test. The   
laboratory    studies   suggested   that   there    was   a   relationship   
between    the   presence   of   these    unusual    antibodies    and    bleeding    
tendencies, because   the   patient   blood    did   not   clot   as   rapidly   as   
normal; the   term   lupus   anticoagulant   was   used   to   describe   this   
clinical   condition. 
  
It   has   been   shown   that   this   antibody   is   only   present   in   a 
small   number   of   LE   patients   and    that   blood-clotting   complications 
occur  in   patients    with   these   antibodies   rather   than    the   bleeding    
complications    one   would    expect   from   the   laboratory    results.  
Although   the   actual    mechanisms   remains   to   be   determined,   
antiphospholipid   antibodies    can   attack   platelets    or   blood   vessel   
cells   which    may   cause   the   formation   of   small   blood   clots. 5 
The   association   between   the   presence     of   the   lupus   
anticoagulant   and   blood   clots   has   stimulated   the   development   of   
more   sensitive   tests   for   the   detection    of   antiphospholipid   
antibodies.  Studies   suggest   that   prolonged   increased    levels   of   
antiphospholipid    antibodies   are   associated    with   a potential   risk   of   
both   arterial   and   venous   blood   clots   or   are   a consequence     of     
some other  previous   clinical   event   remains   controversial. 
The   lupus    anticoagulants, anticardiolipin   antibodies   and    anti 
beta 2  glycoprotein  1  antibodies    are   autoimmune   antibodies   against   
phospholipids   or   plasma  proteins   bound   to   anionic   phospholipids   
and  are a cause of  a clinical   paradox   of   thromboembolic    disease   
called  the   antiphospholipid    syndrome   (APS).  
  Antiphospholipid    antibodies   are   found   among    young, 
apparently    healthy    individuals    at   a prevalence    of    1-5  % for   both   
anticadiolipin   antibodies    and    lupus   anticoagulant.  The   presence    of    
antiphospholipid    antibodies   increases    with   age   and    with   co-
existent   chronic    disease.  The   prevalence    of    antiphospholipid     
antibodies    is    considerably    higher     in    patients    with    SLE. 6     
 
 
  
Pathogenesis   of   thrombosis   in   APS: 
The following mechanisms have been demonstrated  in  vitro:    
• Binding   to   vascular endothelium. 
•   Inhibition   of   prostaglandin  I   release. 
•  Inhibition    of   fibrinolysis. 
•   Interference   with   the   phospholipids  - dependent    protein C 
activation. 
• Interference   with the   anticoagulant    effect    of    activated    
protein   C. 
  
Recently, it   has   been    shown    that   phospholipids   may   not   be   
the   target   antigen    for    many    of    these    antibodies, but    a protein    
on   which   epitops     become       exposed     only    when    the    protein    
itself   becomes      bound    to   negatively    charged   antibodies.   Beta 2   
glycoprotein 1  is  such   a phospholipids   binding   protein    that    also   
has   anticoagulant    properties .  7  
Several   theories   exist   in   an attempt    to    explain    the    cellular    and   
molecular   mechanisms    by    which   antiphospholipid    antibodies    
promote    thrombosis; activated    endothelial    cells, oxidant- mediated   
injury   to   the   vascular    endothelium, direct   interference   in    the    
phospholipids   mediated   regulation of   coagulation   and   a mechanism   
similar    to   the   paradoxical    thrombosis   of   heparin - induced   
thrombocytopenia. The   common   pathology, however, is   a characteristic    
thrombotic    microangiopathy   with   minimal   vascular    or    perivascular    
inflammation. This   change   in   the   architecture   of   both   small   and   
  
large   arteries   is   the   nidus   for   in situ    thrombosis    from   which   
emboli   can   originate.  
There are   two   types   of    APS; primary   and    secondary.   While 
people   with   primary   APS   have   no   other   associated    condition, the    
secondary    form   is    associated    with   another     immune   disorder,  
such  as   SLE,  viral   infections   or   induced   by    medication  e.g.  
chlorpromazine.  
In    different    studies, 8-65   per cent    of   people    with   lupus    
have   the    lupus    anticoagulant, and   25-61   per cent   have    
anticardiolipin   antibodies, these   antibodies   were   first    discovered    in   
people    who   have   lupus, but   it   is   not   necessary    to    have    lupus   
to   have   these   antibodies.  8 
Prevalence   of   antiphospholipid   antibodies: 
  Although    antiphospholipid    antibodies   are   associated   with   a 
propensity   for   thrombosis   and   with   various   autoimmune   disorders, 
they   can   sometimes   be   found   in   normal   a symptomatic   individuals   
.Normal    individuals    occasionally   have   elevated   levels   of   either    
IgG  or    IgM   acl.  In   one   study, the   prevalence   was five percent on  a 
first test but only  two  percent on retesting . Increased levels of  IgG  or  
IgM   acl  have  been  observed in  12 to  52 percent  of  the  elderly 9.     
      Recently the antiphospholipid  in  stroke  study  group  demonstrated  an  
extremely high  prevalence  among  subjects  older  than  65 years. The 
significance of this finding is still   unclear.  It had been suggested that  acL  
in  the  middle -  aged  and  elderly partly  belong  to  a class  of  natural  
autoantibodies   without  pathogenic  complications.  Conceivably, they 
could  also  be  associated  with  clinically  unexpected  ischemic  brain  
damage  some  state  of  hypercoagulability.  Focal changes of the brain   
  
parenchyma are a common MRI  observation  in  normal  subjects, and  their  
frequency  is   strongly  age  related . Only recently has the presence of such   
abnormalities  been  linked  to  slowing  of   mental  processing,  which  may 
be  another  accompaniment  of  aging.  It might therefore be speculated that 
an  association  exists  between  the  presence  of  acL, silent  cerebral  
damage ,  and  cognitive  impairment  in  older  persons . 9  
Associated disorders :  
     Antiphospholipid antibodies have been noted in increased frequency in 
patients with SLE. Approximately 31% of patients have LA, 23-47% have 
acl, & 20% have antibodies glycoprotein 1. on the other hand roughly 50% 
of patients with LA have SLE.APA also occur with increase frequency            
(5-10%), in women with greater  than three  spontaneous  recurrent  
abortions .  10 
Autoimmune  and  rheumatic  diseases: 
• Haemolytic   anaemia . 
• Idiopathic  thrombocytopenic  purpura. 
• Juvenil  arthritis. 
• Rheumatoid  arthritis ( 7 -50 % ).    
• Psoriatic  arthritis (28 % ).        
• Scleroderma ( 25 % ). 
•  Sjogren   syndrome  ( 25 - 42 % ). 
• Behcet syndrome  (7 -20 % ) . 
• Mixed  connective  tissue  disease (22 % ) . 
• Polymyositis  and  dermatomyositis . 
• Polymyalgia  rhumatica (20 %) . 
• Osteoarthritis (less than  14 %) . 
  
• Occasionally in gout and in multiple sclerosis. 
• Chronic discoid lupus. 
• Esinophilia  myalgia and toxic oil  syndrome . 
• Raynauds   phenomenon. 
Infections and drugs:  
            These   are usually IgM   acL antibodies but not anti beta -2  
glycoprotein  1  antibodies,  they   may   occasionally   result  in   thrombotic  
events .     
     These infections include hepatitis  A  and  C  virus ; pneumocystis  cranii; 
infectious  mononucleosis  rubella; syphilis; leptospirosis; and  kalazar 
.Among  the  drugs  that  are  implicated  are  phenothiazines; phenytoin ; 
hydralazine;  procainamide; quinidine; quinine; dilantin; alpha  interferon; 
amoxicillin  and  propranolol.11 
Genetic predisposition: 
Relatives of patients with APS are more likely to have these 
antibodies.  One report; evaluated 83 relatives of   23 patients; 29 (33 
percent) had  acl . In addition; there is a strong association of APL with 
HLA-DR  in  canadaian; German; Italian; and  Mexican   patients  and  with  
HLA-DQ7  in American  and  Spanish  patients 12. 
APS may be associated with genetic or acquired activated protein C 
resistance. Some studies   suggest that activated protein C resistance can act  
synergistically  with  antiphospholipid  antibodies  to  be  prothrombotic  in  
children  with  SLE . 12  
 
 
 
 
  
Clinical features:                
The APS can lead to a variety of clinical manifestations; including 
venous and arterial thrombosis; recurrent spontaneous miscarriages; and 
thrombocytopenia. Infrequently, primary antiphospholipid   syndrome can  
result  in  multiorgan   failure  because  of   multiple  vessel  occlusion . 
Thrombosis: 
         Thrombosis  can  occur  in  virtually  any  vascular  bed  in  the  body.  
Venous thrombosis are more common  than  arterial  thrombosis; commonly  
affecting  the  calf  causing  deep  venous  thrombosis  which  is  the  
presenting  feature  in  32 %  of  people  diagnosed  with  APS and 
antiphospholipid  antibodies  can  be  detected  in  10 %  of  all  patients  
with  venous  thrombosis . 13 
         Renal, hepatic, axillary, subclavian   and retinal veins or the vena cava 
may be involved. The most common site of arterial thrombosis is the  
cerebral  circulation, but  the  coronary,  renal, and  mesenteric  artery   and  
arterial  bypass  graft  occlusions  have  also  been  noted. 
         Recurrent  events  are  common  in  APS. Initial arterial thrombosis  
tend  to  be  followed  by  an  arterial  events  and  initial  venous  
thrombosis  by  venous  events.  The factors that determine the  predilection  
for  the  venous  or   arterial  circulation  are  not  known . 14  
          A prospective  study  of  360  patients  with  APS  noted  that  34  
experienced  a recurrent  thrombotic   event  during   a median  follow up  
period  of   approximately   four  years. Thrombotic   events were  
responsible  for  five  of  eight  deaths. Another prospective  study  of   81  
patients  with  apl   found  that  31 %  had  recurrent  ischaemic  strokes; 
patients  with  high  titers  of  acl  had  a  shorter   time  to  recurrence . A 
second  prospective  study  of  412  patients  presenting  with  a  first  
  
episode  of  venous  thromboembolism  found  that  the   risk  of  recurrence  
was  twice  as  high  among  patients  with  acl  compared  to  those  without  
such  antibodies. 15 
Cerebrovascular: 
       Single  or  multiple  transient  ischaemic  attacks  and  or  strokes  occur  
and  often  recur  in  the  APS, resulting  in  a variety  of  temporary   or   
permenant   neurologic  deficits. These  include  transverse  myelopathy; 
epilepsy; chorea; dementia; Gillian bare  syndrome, transient  global  
amnesia, seizures,  motor neuron disease, depression,  amaurosis  fugax   and 
pseudotumor  cerebri. Some  of  these  features  results  from  arterial  
thrombi; while  others  are  caused  by  cerebral  emboli  due to  libmansacks  
endocarditis. 
       Central nervous system involvement  in  APS  is  strongly  associated  
with  small   high – density  lesions  on  MRI  suggestive  of  a vasculopathy; 
they  are  difficult  to  be distinguished  from  multiple  sclerosis  which  may  
also  have  apl   antibodies. The APS  should  be  particularly  suspected  
when  stroke  occurs  in a young  patient  without  significant  risk  factors.  
In  one   report  antiphospholipid  antibodies  were  found  in  25%   of  
patients  under  the  age  of  45  with  a cerebrovascular   accidents  of  
unclear  aetiology. 16 
         The relative risk of stroke associated with the presence of   
antiphospholipid   was assessed   using clinical   data   and   frozen   sera  
from   2ooo   subjects, there   was   a modestly   increased   risk  of  stroke   
associated  with  the  presence   of   antibodies   of   antibodies   of   the    
IgG   type   that    were   dependent   upon   the   presence   of   beta –2  
glycoprotein  1.  The   presence   of    antibodies    that   bind   beta –2  
glycoprotein 1   in   the   absence   of   phospholipids,  or   those   that   
  
bound   to   phospholipid   in   the   absence   of   beta -2  glycoprotein  1   
were   not   associated    with    an   increased    risk    of    cerebrovascular    
events.  17 
         Neurologic    events   associated    with    antiphospolipid     antibodies    
(APAS )    include   transient   ischaemic   attacks   ;  stroke   and    vascular    
dementia    in   individuals    much    younger    than   is   typically    
observed   with   these   disorders.  
         A study    conducted    in    Detroit; USA   evaluated    27   non- elderly   
adults   with   APAS   but   without   concurrent   disease   process   or   
history     of    neurologic    events    and   27    age   and education  - 
matched    controls.  It   indicated   group   differences   in   executive   
functioning; verbal   learning   and   memory; and   visuospatial   ability.  In   
contrast; gross   attentional   processes   and   fine   motor   skills   appeared   
unaffected    by    the   syndrome.  Moreover, the    frequency    of    
impaired    neuropsychologic   performance    was   greater   among   
individuals    with   APAS    than    among   controls.   The   presence   of   
cognitive    deficits   in   other wise   a symptomatic    patients    with    
APAS    indicates    a preclinical    phase   of    neurologic    involvement   
and   may   prove   to   be    the   most   sensitive   markers   of   the    
syndrome. 18 
Ocular   findings: 
      Retinal    findings   in    APAS   include   venous   tortuosity; cotton – 
wool   spots; retinal   vein   occlusions; and   retinal   artery   occlusions.  
Other    fundal    findings may   include   optic   nerve   edema,  vitreous   
haemorrhage,  choroidal  vascular   occlusions,  conjectival   telengectasia,  
episcleritis, and  keratitis  have  also   been  reported.   Visual acuity    may  
  
be   reduced.  These   symptoms   are   caused   by   thrombotic    tendency   
of   patients   with   APAS.  19 
       Stroke is   often   the   initial   manifestation   and   is   the best   
described  .  Echocardiographic   evidence   of   mitral   valvular   lesions, 
aortic  valvular   abnormalities   have  been   implicated   as   sources   for    
cerebrovasculr    events.  However, many   patients   show   no   evidence   
of   cardiac    pathology   following   cerebrovascular   events, suggesting   
the   role   of   in  situ    thrombosis   as   a causative   mechanism.  
         In   the   antiphospholipid   antibodies   in   stroke   study   group   
(APASS )  ,  angiography   was   done   in   49  of   128   patients ,  half   of   
those    studied   had   intracranial   lesions,  middle   CA   occlusion   were  
the   most    common   arterial   ischaemic   events   were   responsible    for   
most    strokes   with   haemorrhage   being   distinctly    uncommon   ,  in   
this  patient  ,  a haemorrhagic     infarction    was   most   likely   due  to  
necrosis   after   an  intravascular   thrombus. 20   
        A study   conducted in   San Carlo, Milano, Italy, assessing the  
prevalence  of   APA   in  young  patients  with   cerebral   ischemia   of   
undetermined   cause;  it   studied   77  patients,  34  were   positive   for   
apL   to  1  or   more   phosphospholipids.  A significant   number   of    
patients   had   apL   to   anionic   phospholipids.  A small   number   of   
cases   showed    apL    with   specificity    to   neutral   phospholipids, in   17   
cases   positivity   for   only   1  phospholipid   was  demonstrated,  in   
contrast, the   remaining   17   cases   showed   positivity   for   multiple    
phospholipids    and    more   than   1   isotype   was   demonstrated. Fifty- 
nine   patients   were  acL    negative,  of    these  subjects,  18  showed    
positivity    for   apL   to   epitopes    other   than   cardiolipin.   
  
         Antiphospholipid – related   clinical   events   were   also   present   in   
acL  negative   apL  positive   patients ,  two  patients   who   had  multiple   
strokes   both   had   an   isolated   anti- pi  antibody.   It   concluded   that,  
no   statistically    significant    differences   in   age,  sex,  diagnosis                       
(  stroke  or  TIA  ),  or    cerebrovascular   risk   factors    were    observed    
between    patients    who   had    apL    to   a single    phospholipids    and    
1   or   2    isotypes    and    those    with   apL    to    multiple   phospholipids    
and     multiple     isotypes. 21  
          A study    done   in   Austria    studied    one-hundered eighty    
subjects, 77.3 % had    negative, 15 % low   positive    acL   positive    and    
7.7 % moderately   high   positive   acL   titers.  acL    positive   patients    
were   slightly   older    and    had    a somewhat    higher    rate    of   cardiac    
disease    than   acL    negative    subjects  .  Migraine    without    aura   was   
reported    by   ( 8.3 % )  with    negative   ,  (11.4 % )   with   low   positive,  
and   ( 11.1 % )   with   moderately   high   positive   titers.  The acL   status    
of    subjects    had    no   influence   on    the   MRI   results, overall, silent    
ischaemic    brain   damage   defined   as   either    infarcts,  lacunes   or   
WMH   was   noted   in   51 %   with   negative  , 51.4 %   with   low   
positive    and   66.7 %   with   moderately   high   positive    titers   .  In   the   
neuropsychological   test,  acL   positive   study    participants   obtained    
worse    scores    than    their   acL    negative    counterparts    on   almost   
all   tests . 
       Preliminary    data   also   suggest    that   antibodies   directed    against   
phosphatidylserine   may   react   directly   with    central    nervous   system    
tissue   and   may   be   more   specifically   associated    with    ischaemic    
stroke.  22 
  
       Immunological    factors   may   contribute   not   only   to   thrombosis   
but   also   to   atherosclerosis,  mediated   by   apL   , patients   with   APS   
have   increased    levels    of    antibodies    to   oxidized    LDL,  associated   
with   progression   of   atherosclerosis   and   risk   of    thrombo-occlusive    
event.  Antibody   responses   to   phospholipids,  oxidized   LDL,   beta -2  
glycoprotin 1,  prothrombin, and  endothelial   cells   partially   overlap   and   
may   reflect   a broadening   spectrum   of   antibody   associated   
atherosclerotic   disease. 23 
       Recent   reports   demonstrating   that   the   presence   of    antibodies   
against    phospholipids, oxidized   LDL, and    prothrombin    is   a predictor    
of    myocardial    infarction   support    an    important    role    of    APL    in    
the   pathogenesis    of    thrombo- occlusive   events.  It   is    possible   that    
the   presence   of   certain   APL   alters   the    threshold   for   thrombosis    
and   thus   creates a permissive    thrombotic    environment. 
          In   a study   reported   in   stroke, high   prevalence   of    
antiphosphatidylinositol    antibodies   was   identified    in   young   
population    of    cyptogenic    stroke    or    transient   ischaemic    attacks    
patients, high   prevalence    of   antibodies   directed    to   1   or    more   of   
these    phospholipids   was    found   in   this    population. 23   
        In one report, APLAs were found in 25 percent of patients under the 
age of 45 with Cerebrovascular accident of unclear aetiology. A similar 
prevalence of approximately 20 percent positivity for APL was noted in a 
second report of stroke victims under age 50.  23 
          A study   conducted   in   Texas    studied   strokes   in   young   
showed   that,  a mong   the   160  stroke   patients   , 63   had   at  least   1    
possible   cause ;  large –artery   atherosclerosis,  16 ,  cardioembolism,  18; 
lacune   and   other   causes.   Fifty   were   inderterminate.   Other   causes   
  
of   stroke   include   haematologic   disorders   and   nonatherosclerotic    
vasculopathy   (e.g. vasculitis   and   dissection), migraine, oral   
contraceptive   use,  drug  abuse, and   stroke  associated   with   the   
postpartum   state. 24 
        Anticardiolipin   IgG   antibody   was   the   isotype   most   strongly   
associated   with    stroke.  acL   of   any   type   was   seen  in   43   cases   
and   62   controls  ,  LA   in   29   cases   and   38   controls,  and   either   
acL    or  LA  in   61   cases   and   86   controls. 
         There   was   no   evidence   for   effect   modification   by   age, 
current   cigarette    smoking, hypertension, diabetes, angina, ethnicity, body 
mass index , and HDL levels  . After adjustment   for   these factors, the 
relative odd ratio of stroke for women with acL immunoreactivity of any 
isotype or a LA was 1.87.  25 
         To   test   the   prevalence  of antiphosphatiolylinositol   antibodies in 
young patients with cerebral  ischaemia of undetermind cause , a study was 
performed in san carlo , italy.  Seventy – seven non –SLE for patients had 
apl to one  or  more of the following antigens ,23 .4% to cl  18.2 % to ps  
15.6%to PG ,14.3%  to PA, and 28.6%  to pi . fifty  nine patients were acl 
negative  of these subjects 23.4% showed apl to noncardiolipin epitopes. PI 
was the  specificity with highest pervalence in all 6 patients anti – PI 
antibody were the only detectable apl . The binding of apl to the different 
antigens was B2-GPI dependent. 26  
        Data demonstrate a high prevalence of apl in young adults with cerebral 
ischaemia of undetermined cause PI was the specificity with highest pre 
valence,   suggesting  that  anti PI  antibodies  may  be  an  immunological  
marker  in  young  patients  with  Cerebrovascular  disease. 26 
  
            Lupus anticoagulant and antiphospholipid antibodies are associated 
with thromboembolic phenomena in individuals both with and without 
systemic lupus. 
             A 32 year – old women (the index case) with lupus anticoagulant, 
multiple cerebrovascular events , and a family history of premature stroke 
raised the posibility of a familial diathesis. Histories, interviews, 
examinations, and blood tests were obtained for 23 members of four 
generations of her family. Four individulas had suffered strokes three more 
had suffered neurologic symptoms, and five asymptomatic individuals had 
antiphospholipid activity in their blood. In addition, a cousin of the index  
case was found to have systemic lupus and antiphospholipid activity . 
Elevated concentrations of vonwillebrand factor antigen were found 
associated with some positive LA assays, the highest concentrations in the 
two individuals with stroke. The characteristic presentation of the index case 
and her good response to treatment suggest that further studies of families in 
whom antiphospholipid antibodies may present a risk factor for stroke is 
worthwhile . 27 
          A study conducted in  Barcelona, Spain, 146  patients  with cerebral  
ischaemia  were  studied, vascular  risk factors for  stroke with clinical and 
laboratory findings, particularly antiphospholipid antibodies were  
compared. Ten patients were positive for at least one antiphospholipid 
antibody, one patient had systemic lupus, one had rheumatoid arthritis and 
the remaining eight fulfilled the criteria for the diagnosis of primary 
antiphospholipid syndrome. These patients were predominantly males, not  
necessarily young , and 50 %  of  them did not  have any other vascular risk 
factor, there  were no significant  clinical or paraclinical  differences 
between these patients and those without antiphospholipid antibodies. 
  
Outcome in the 10 patients was good , and platelets antiaggregating  drugs 
proved to be useful in preventing further cerebrovascular ischeamic  
events.28  
           To test the relation between  thrombophilia  and  ischaemic  stroke , a 
study  was  performed  in Saint Antoine hospital , France , forty  patients  
were  tested , six  cases of  thrombophilia  were  found ; 1 protein  c  
deficiency , 1 protein  s deficiency , and  4 activated protein c resistance 
With heterozygous  factor  v laiden    mutation 0nly 1 case was found in the 
group l patients with idiopathic ischaemic stroke in the other 5 there was 
another cause or risk factor . three patients had increased anticardiolipin 
1with SLE and 2 with primary antiphospholipid  syndrome ; 2 of these 3 
patients also had factor v leiden  mutation. 
        Congenital or acquired causes of thrombophilia are almost invariably 
associated with other predisposing factors, so these abnormalities should be 
looked for in patients with cerebral ischaemia , whether a cause is found  or 
not, and their presence should  not deter  the  search  for  other potential  
causes .The detection of  such  abnormalities  has  major  practical  
consequences  on  the long–term  management  of  patients  to  prevent  
further  thrombotic  episodes . 29  
            55 young  patients  with  ischaemic  stroke  were studied  in  Italy  
for  LA and  acl  antibodies,  ten  patients, all with  stroke  had  
antiphospholipid  antibodies. Antiphospholipid antibodies were  
significantly  more  frequent  in  women than  in  men, two  patients  had  a 
new  diagnosis  of  SLE , non of  patients  with  antiphospholipid   Abs had  
extacranial  lesions  on  angiography. Patients with  apl antibodies  had  
significantly  more  prior  cerebral  events  and  by  survival  analysis,  
  
higher  probability  of  cerebral  ischaemic  or  systemic  thrombotic  
events.28 
            A study was conducted in  San carlo, where Doppler U|S was done in 
32 patients , an ulcerated, non- stenosing  atherosclerotic plaque of internal 
carotid artery was observed in three patients, one at the intracranial level , 
and two at the extracranial level, a stenosing ( more than 50 % ) lesion of 
internal carotid artery  at the  extracranial level was found in one patient . 
stenosis of  more than 70% are linearly associated with increased risk  of 
distal brain infarct. Carotid endarterectomy is effective in reducing the risk 
of subsequent ipsilateral stroke. 27. In fact an  IgG –apl  titer of  higher  than  
10  GPL  units  has  been  shown  to  be  an  independent  risk  factor  for  
the  first  stroke  by  the  antiphospholipid  antibodies  in  stroke  study  
group  ( APAAS)   Iran . It occurs  mainly  at  a younger  age  than  the  
typical     atherothrombotic   cerebrovascular   events  with  women  being  
affected  slightly  more  than  men. The  median  age  of  our  cases  was  30  
years  with  64%  within  the  age  range  of  29 – 37  years , the  female  to  
male  ratio was  2: 1 . Paresis was the most common presentation during  
both  the  acute  and  established  stages  . Secondly   cerebellar   signs  
which  rarely  reported  in  the  literature  .  sensory  disturbance  ( numbness  
and  paresthesia  )  was  the  third  most  common  presentation . INO , optic 
neuritis  were found in two patients ,motor dysphasia in three  patients  and  
disturbed level of consciousness in only  one patient. 30 
          Epilepsy may occur in  APS  due to  non-thromboembolic phenomena,  
apls  have  been  demonstrated  to  bind  directly to  cat  brain se ra  
containing  apl  from  SLE  patients  with  seizure, has  been  shown  to  
reduce  a GABA  receptors  mediated  chloride  in  snail  neurons.   Four of  
the patients  had  epilepsy,(grand mal seizures  and  myoclonic  jerks  in  
  
one) , motor  dysphasia  was  present  in  three  patients  , and  was  the  sole  
clinical  manifestation  in one.30 
         The initial  report  linking antiphospholipid  antibodies  to  seizures  
showed  the presence  of  LA  ( but  not acl )  in  patients  with  late onset  
seizures ,subsequent  reports  have  shown  that  LA  h as  stronger  link  to 
thrombotic  events  than  do  acl. 
         The incidence  of  stroke  in  young  adults  is  estimated  to be 62 per 
100\000  with  one  study  showing  that  27 %  are  idiopathic  strokes  and  
31 %  are  embolic  with  apl   a possible  cause  for both . One  study  has  
shown  that  cerebrovascular  events  account  for  14 %  of  all  late – onset  
seizures . Progressive  cognitive  impairment  and  mood  changes  have  all  
been  reported .  31 
Venous  thrombosis: 
           Antiphospholipid  antibodies  can  be  detected  in  approximately  10 
%  of  all patients  with  venous  thrombosis  .  The  incidence  of   venous   
thrombosis  may  correlate  with  the  level  of  anticardiolipin  antibodies  .   
One  study  found  that  venous  thrombsis  occurred  in  44 %  of  patients  
with  high  titers  of  acl.  Thrombosis  occurred  in  42 %  of  those  with  
antiphospholipid  antibodies,  51 %  with  lupus   anticoagulants ,  31 %  
with  anticardiolipin  antibodies.  32 
Pulmonary  disease: 
   Multiple pulmonary complications can occur in patients with  SLE  
and  the  APS  including    
• Pulmonary  embolism  and  infarction , which  occur  approximately in  
one _  third  of  patients  with  recurrent  DVT .  
• Thromboembolic  and  non-thromboembolic  pulmonary  hypertension, 
possibly  leading  to  right -  sided  heart failure .  
  
• Pulmonary  arterial  thrombosis.  
• Pulmonary   microthrombosis. 
• Adult  respiratory  distress  syndrome . 
• Intra alveolar  pulmonary  haemorrhage .  
• Fibrosing  alveolitis . 
• A postpartum  syndrome ,  characterized  by  spiking   fever , pleuritc  
chest  pain, dyspnoea  and  pleural  effusion  and  patchy  infiltrates  on  
chest  radiographs .  
Cardiovascular  disease:      
          Patients  with  APL  commonly  have  cardiac  disease , including  
valvular  thickening  and  the  development  of  vegetations . The  mitral   
and  aortic  valves  are  most  commonly  affected,  possibly  leading  to 
valvular  insufficiency.  Antiphospholipid antibodies have been  
incriminated in intracardiac  thrombi,  pericardial  effusion , cardiomyopathy  
and  peripheral  vascular   disease .  
         In  one  report , 20%  of  patients with  nonautoimmune   ischaemic  
heart  disease  had  anticardiolipin  antibodies   of  uncertain  significance.   
In  another  study   of   37  patients  with  unstable  angina,  30%  had  
antibodies  to beta – 2  glycoprotien – 1 .  A study  of  nearly   2000  subjects  
strongly  suggests  a pathogenic  role  for  beta – 2  GPI  dependent  IgG  
type  antiphospholipid  antibodies  in  some   patients  with  ischaemic  heart  
disease.  Up  to  20%  of  younger  people  who  have  a heart  attack  have  
antiphospholipid   antibodies.  33 
       A study conducted  in San carlo, where echocardiography was done in 
61 patients and did not show any possible additional source of cardiac 
embolization such as atrial or appendage thrombi or valvular vegetation.  
  
       A study in stroke published by the American heart association stated 
that , cerebral infarction in patients with atrial  fibrillation is presumed to 
result from embolization of intracardiac thrombi, which most commonly 
form in the left atrial appendage. autopsy data indicate that stroke is a 
possibility throughout the life of persons with a history of atrial fibrillation.34    
Haematologic: 
           Thrombocytopenia  and  thrombotic   thrombocytopenic  purpura  
have  both  been  reported  in  APS.  A review  of  13  studies  of     869  
patients  with  SLE  found  that  thrombocytopenia  was  more  common  in  
those  with  antiphospholipid  antibodies  ( 37 % ) ,  the  lupus  anticoagulant  
( 55 % )  , and  anticardiolipin  antibodies  ( 29 % )  than  in  those  without  
these  antibodies. The risk of  developing  the  APS  is  increased  in  
patients  with  ITP  who  have  antiphospholipid  antibodies  or  lupus  
anticoagulant  activity  .  One  prospective  study  of  82  patients  presenting   
with  ITP  noted  that  only  one – quarter  to one  - third  of  those  with  
such  antibodies  remaind  free  of  thrombotic  events  during  the  
subsequent  five  years  compared  to  96 to  98  percent  in  those  who  did 
not  have  these  antibodies.  Patients  with  ITP  and  persistent  presence  of  
a lupus  anticoagulant  appeared  to  be  at  highest  risk , 45 percent  of  such  
patients  developed  APS  during  five  years  of  follow – up  . 
Bleeding  episodes: 
           The  possible  presence of prothrombin antibodies should be suspect 
when a patient with known antiphospholipid antibodies develops bleeding 
manifestations  rather than thrombosis.  35 
Renal disease: 
The incidence of renal disease  in the APS is   unclear . 
• Thrombi in the glomerulus and small arteries. 
  
• Arterial or venous thrombosis in the intrarenal vessels or in large 
artery branches. 
• An increased incidence of graft thrombosis in hemodialyzed patients.     
 Gastrointestinal: 
              Patients with APS antibodies may have ischaemia  involving the 
oesophagus, stomach, duodenum, jejunoileum  or  colon  resulting  in  
gastrointestinal  bleeding, abdominal  pain,  oesophageal  necrosis  with  
perforation , or  giant  gastric or  a typical  duodenal  ulceration.  
 
Cutaneous: 
               AP  antibodies  have  been  associated  with  many  cutaneous  
abnormalities  including  livedo reticularis, livedo  vasculitis,  cutaneous  
necrosis  and  infarctions, thrombophlebitis,  gangrene  of  digits,  skin  
ulcerations, subungual  splinter  haemorrhages,  and  Degos  disease 
(malignant  atrophic  papulosis) .   35 
APS  and  pregnancy : 
             APA  have  been  linked  to  poor  reproductive  performance  e.g  
infertility,  recurrent  miscarriage , placental  insufficiency , intrauterine  
growth  retardation  and  early  separation  of  the  placenta  and   HELLP  
syndrome. An evidence has confirmed that  patients  who  experience  IVF  
failure, often  have  elevated  APAs, also  women  with  pelvic  
endometriosis   or  unexplained  infertility  tend to  have  elevated  APAs . 
       It   has been  well  established  that  APAs  bind  to  human  trophoblast,  
phosphatidylethanolamine   and  phosphatidylserine  are  two  important  
phospholipids  that  serve  as  adhesion  molecules, they  bind  to  
trophoblast, inhibiting  its  invasive  potential  and  interfering  with  
cytotrophoblast  to  synctiotrophoblast  differentiation. This  phenomenon  
  
has  the  effect  of  seriously  compromising  the  respiratory,  metabolic, and  
endocrine  functions  of  cynctiotrophoblast. A 21  percent  of  women   
presenting  with  three  or  more  pregnancy  losses . 9  pregnant  ladies  with  
antiphospholipid  antibodies  are  more  prone  to  develop  strokes  or  
pulmonary  embolism .  
      Risks  for  several  complications  are  increased  in  women  with  apl  
and  include;  strokes,  blood  clots  and  pregnancy – induced  hypertension  
(occurring  in  as  many  as  50%   of  women  with   apl).  36 
     A study published in up to date, stated that some patients with SLE have 
a false positive test for syphilis. Such patients have been noted to have fewer 
successful pregnancies, an increased number of thrombotic events, livedo 
reticularis and migraine. 
    It occurs because the syphilis antigen used in the test is embedded in 
cadiolipin so a reaction against this molecule will be incorrectly interpreted 
as being directed  against the treponemal  antigen .the syphilis test should 
not be used  to  screen for APS since it has a low sensitivity  and  
specificity.38  
Autoantibodies:      
       Antiphospholipid antibodies are a heterogeneous group of  
autoantibodies  of  IgG  ,  IgM  and  IgA  classes.  These  antibodies  can  be  
directed  to  anionic  phospholipids , phospholipids  protein  complexes  and  
cofactors  in  the  absence  of  phospholipids. Three different autoantibodies 
to  properly  diagnose  APS  or  to  assess  the  risk  for  thrombosis  or  
recurrent  fetal loss. These include anti-cardiolipin (acl), anti-Beta2 
Glycoprotein I (B2GPI), and antiphosphatidylserine (aps). 
Anticardiolipin antibodies (acl) are a heterogeneous group of 
antibodies that react with negatively charged phospholipids. They are found 
  
also in patients with syphilis and other infectious diseases who have no 
evidence of coagulation disorders. 
Beta2 Glycoprotein I (B2GPI) was identified as a necessary cofactor 
for antiphospholipid antibody binding in immunoassays. 
Phosphatidylserine is a more physiologically relevant phospholipid 
due to its presence in cell membranes of endothelial cells and platelets and 
its role in the coagulation cascade. 
Lupus anticoagulant test should be done first before embarking with 
these antibodies test. APL may play a role in atherosclerosis. Antibodies to 
prothrombin  are increased risk of myocardial infarction. APL (particularly 
B2GPI an oxidized LDL) but these antibodies do not appear to interfere with 
coagulation in the sub endothelial space, oxidized and phagocytized by 
macrophages forming fatty streak, the first step in atherosclerosis. 
Antibodies to oxidized LDL increased oxidation of LDL, a process that 
increases macrophage phagocyte formation.  39     
Diagnosis: - 
Definite APS is considered present if at least one of the following 
clinical criteria and at least one of the following laboratory criteria are 
satisfied. 
Clinical: 
Either one or more episodes of venous, arterial, or small vessel 
thrombosis, and/or morbidity with pregnancy. 
Laboratory: 
The presence of either 1gG and/or 1gM anticardiolipin antibody, 
and/or lupus anticoagulant activity, the antibodies and/or activity should be 
found on two or more occasions, at least six weeks apart. 
  
In one study, the prevalence of 1gG acl was 6.5 percent on a first test in 
522 randomly selected normal blood  donors ; 4% remained positive nine 
months later. In another report patients with a first venous thromboembolic 
event, the incidence of acl was similar to the control population. In 
comparison, lupus anticoagulant activity was much more common in the 
patients with venous thromboembolism. 
? Lupus anticoagulant activity, which is another wise unexplained 
prolongation of the activated partial thromboplastin time that is not 
reversed when the patient’s plasma is diluted 1:1 with normal platelet. 
Free plasma (this is a procedure that will reverse the clotting 
abnormality associated with factor deficiencies). 
? A false positive serology for syphilis. 
? The presence of anticardiolipin antibodies. 
? The presence of anti B2 – glycoprotein 1 antibody.   40 
 
Catastrophic antiphospholipid syndrome: - 
It is defined and documented in 1992, is a potentially fatal 
complication seen in patients with antiphospholipid antibody. It may  arise 
de novo in patients not previously suspected as having an antiphospholipid 
syndrome, or it may complicate the course of patients currently treated for 
this syndrome. Precipitating or trigger factors have been identified in 55% of 
patients; the most common of these factors is  infection . 
The precipitating factors should be avoided or energetically treated in 
patients with the antiphospholipid syndrome . in order to prevent this 
catastrophic course. 
The clinical manifestations are those of multi organ  failure , and  
unusual vessels or organs can be involved. 
  
Treatment of the condition with emphasis on effective 
anticoagulation, intra venous immunoglobulins  or  plasma exchange, should 
be aggressive to achieve  a satisfactory outcome  Despite all available 
therapeutics options at this time, the mortality is still high (greater than 
50%).  41 
Treatment:  
At the moment   antiphospholipid syndrome cannot be  cured but the 
effects can be controlled. Commonly used drug are antiplatlets and  
anticoagulants . 
People with antiphospholipid  antibodies but without a history of  
clotting : 
Are recommended low-dose Aspirin (75-100mg) daily . 
Some studies suggest that some people go on to develop clots despite 
taking Aspirin. 
• People with APS who have a history of clotting : 
are at risk of recurrence, so they are given long term  
warfarin therapy with regular INR check. 
• Women with recurrent miscarriages, but without a history of 
clotting  : the traditional treatment is low dose Aspirin . 
Heparin is increasingly being used especially for those who 
have had previous miscarriages in mid to late pregnancy, or 
other pregnancy complications such as pre-eclampsia. 
• Studies showed that intermediate – to – high intensity 
warfarin therapy (INR between 2.6 and 3.0) reduced the 
incidence of thrombotic events by approximately 75 percent, 
where as low-intensity warfarin or aspirin seemed to be 
without benefit. 
  
The advantages of anticoagulation after a first   thrombotic events 
must be weighed against the risk of bleeding with intensive warfarin  
therapy . In studies, the incidence of bleeding episodes was much lower than 
the absolute benefit of thrombosis prevention. In addition many patients 
have major thrombotic recurrences when anticoagulation is stopped. 
Some studies have suggested that recurrent venous thromboembolism 
is prevented by maintaining the INR under three, or even under two. 
Some experts feels that anticoagulation can be discontinued if the 
APL become negative or titers significantly  decrease (40%) upon 
retesting.42 
Prophylaxis in patients without thrombi:   
The  incidence  of  thrombotic  episodes  in  asymptomatic  patients  
has been reported  to range  from  10 percent  to  as high as  75 percent  
when  antibody  titers are very high  . One  prospective  three year study  of  
90 patients  with  SLE found  34  who  had at least one  positive  test for  acl; 
however , the  presence  of  acl did not predict  an  APS  thromboembolic  
event . 
Thus, prophylactic therapy for asymptomatic individuals with  
anticardiolipin  antibodies  is not  generally  recommended . However, 
women  should be  advised  to avoid  oral contraceptives. 43    
Management of antiphospholipid syndrome during pregnancy:  
Because of the higher risks for stroke, pregnancy loss, and other 
complications with apl , mothers need close monitoring of the disease. 
If the women has  antiphospholipid antibodies and is pregnant for the first 
time, or has had normal pregnancies in the past, no treatment may be 
advised. However, if she has had miscarriages in the past, she should be 
given aspirine , prednislone , and /or sub cutaneous heparine.44 
  
 
 
OBJECTIVES  
 
 
 
1) To determine the incidence of APLAs among adults Sudanese IBD 
patients. 
 
2) To find out any special features characteristic to this special group of 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIAL AND METHODS 
 
Patients and  materials : 
 This  is  a cross - sectional, case - controlled  study,  which  has  been  
conducted  in  Elshaab  and  Khartoum  teaching  hospitals  during  the  
period  from  July  2003  till  January  2005. 
Inclusion criteria. 
Patients were selected  randomly, after  taking  their  verbal  consent  
from  those  who  fulfilled  the  inclusion  criteria  which were; 1) Adults,          
2) Documented brain infarcts either by CT or MRI . 
 There were two control  groups,  the  first  group  were  patients  
within  the  same  age  group who have  other  conditions  other  than  
vascular  disorders (such as infectious diseases). The second group were  
adult  individuals  who  were  completely  healthy.  
Sample size:   
 89  cases  of  ischaemic  brain  diseases  were  selected  randomly.          
35  patients  who  suffered  from  conditions  like  infections  or  connective 
tissue  disorders and  another  36  adults   who  were   completely  healthy  
were  included  in  the  study. 
Data  collection: 
 Data  were  collected   using  a simple  direct  questionnaire  filled  by  
the  investigator  himself  ( app. 1 ). 
 The  questionnaire  included  five  main  divisions  ;  patients  
identification, presenting  complaints  , relevant  past  history, full  physical  
examination  then  the  last  section  which  includes  investigations  
requested  such as   blood  counts, ECG, Doppler U/S of the  carotids, lipid  
profile and  serology.  
  
 The lipid profile and  antiphospholipid  antibodies testing  were  
performed  by  a recognized  chemical  pathology  laboratory, done by  an 
accredited  pathologist. 
Technical  data: 
• Sample   material    :   serum. 
• Required  sample  size  :  10microliter of  sample  to be diluted  
1 :  100  with  sample  buffer .  
• Total  incubation time  :  60  minutes  at  room temperature   
(20 -28 c  )  . 
• Sensitivity   :  IgG   and  IgM  :  0.5 u|ml  . 
• Specificity   :  the  antiphospholipid  screen  test  kit  is  specific  
for  autoantibodies  directed  against  phospholipids  or  the  
complex   of   negatively  charged  phospholipids  and  beta - 2  
glycoprotein 1. 
No cross - reactivity  was  observed  to  anti- DNA  antibodies  and  
those  types  of  antibodies  occurring  in  syphilis .  
Principles   of  the  procedure  :      
 Antiphospholipid  screen  (  IgG / IgM  ) is  an  indirect solid  phase  
enzyme  immunometric  assay ( ELISA )  . it  is  designed  for  the  
quantitative  measurement  of   IgG / IgM  class  autoantibodies  directed  
against  phospholipids.   The  microplate  is  coated  with  highly  purified  
negatively  charged   phospholipids  :  cardiolipin  phosphatidyl  serine,  
phosphatidyl  instol  and  phosphatidic   acid.  Antiphospholipid  
autoantibodies  require   beta 2  glycoprotein 1  as  a co-factor  for  binding. 
The  microplate  is  therefore  saturated  with  human  beta 2 glycoprotein 1 .  
  
 The binding of present   autoantibodies,  formation  of  the  sandwich  
complexes and  enzymatic   colour   reaction  take  place   during  three  
different  reaction  phases. 
Normal   values :        
   Antiphospholipid antibodies 
   IgG( GPL  u |ml )                       IgM ( MPL  u| ml ) 
Normal         less than 1o                                 less than 10 
Elevated       more than or equal to 10            more than or equal to 10 
The serum was considered APLAS +ve if either IgG or IgM or both 
antibodies were detected in high concentration.  
Analysis : 
 After that data  were  entered  into  a computer  to  be  analyzed  using  
SPSS system. 
 Results  were  obtained  , represented  statically  and  then  discussed . 
         Lastly recommendations are derived in view of improving the 
management and subsequently the outcome of patients suffering from  
ischaemic  brain  diseases.      
 
 
 
 
  
 
 
 
 
 
  
RESULTS 
 
This study included 89 patients with ischemic brain disease                        
(41 males, 48 females), 35 diseased control and 36 healthy individuals. The 
groups were matched for sex. [Fig.1] 
The study showed that while 34.8% of patients suffering from ischemic 
brain disease (IBD) were found to have positive APLA, 31.4% of the 
diseased control group and 16.7% of the healthy individuals were found to 
be positive for the test [Table 1] .The percentage of +ve  APLAS  is 
significantly higher in the IBD group, compared to the other two group    
(P= 0.05). 
Out of  41 males with IBD, 12 were found +ve for APLAS (29%). This is 
compared to 19 APLAS  +ve females out of 58 with IBD (40 %).  On the 
other hand 36% of males and23% of females in the diseased control group 
were positive. 23% of males &12% of females of the healthy individuals 
were positive for the test as well . [Table 2] 
The highest percentage (71%) of the positive APLA was found among 
the age group 20-29 , the lowest (24%) in those between 40-49 in those with 
IBD .  In the diseased control group, the highest percentage (67%) was in 
those aged  (40-49) and the lowest (10%) was above 60 years.  In the healthy 
control group the highest percentage (50%)was among those aged 50-59 and 
the lowest 0%, in those aged more than 60 years. This difference is 
statistically significant (p.0.01). [Table 3a,b & c] 
At presentation, stroke patients who were APLA positive complained of , 
motor weakness (in 87%) headache (48%), seizures (35%), speech 
disturbance (29%), disturbed consciousness (13%) and vomiting 
  
(9.6%).While patients who were APLA negative presented with motor 
weakness (93%) ,speech disturbance (53%) ,disturbed consciousness (33%) 
,headache (28%),seizures (8.6%),vomiting (6.8%). [Fig. 2]    
In patients with IBD who were APLA positive past history of diabetes 
mellitus was encountered in 23 %, systemic hypertension n 26 %, cardiac 
disorders in 9.7 %, TIA in 6.5 %, DVT in 13 %, abortion n 23 % migraine in 
9.7  %. [Fig. 3] 
In APLA negative with IBD past history of diabetes was encountered in 
16 % of patients, hypertension in 28 % cardiac disorders in 10 %, TIA in 
8.6%, DVT in 2 % ,abortion in 5 % ,migraine in 3 % . [Fig. 3] 
History of diabetes mellitus was encountered in3.8%of positive patients 
compared to 56.3% of the negative group. Hypertension in 33.3% of APLA 
positive patients and 66.7% of the negative group. [Fig. 3] 
Cardiac disorders were demonstrated in 33.3% of APLA positive group 
compared to 66.7% of the negative patients. TIA preceded the stroke in 
28.6% positive and 71.4% negative ones. DVT in 80% positive patients 
compared to 20% of the negative group. Abortion was found in 70% of the 
positive patients and 30% of the negative ones. Migraine was encountered in 
about 60% of APLA positive patients and in about 40% of the negative 
group. This was statistically not significant [P. 0.23]. [Fig. 3] 
Full consciousness was found in 35.6% of APLA positive patients 
compared to 64.4% of the negative individuals, while 60.7% of APLA 
positive patients present with normal speech, 39.3% of the negative group 
had had normal speech as well, normal cranial nerve examination was found 
in about 3.2% of the positive and in 61.8% of the negative group. Normal 
power was detected in 33.8% of the positive and in 66.2% of the negative 
patients. This difference was statistically non significant [P. 0.08] [Fig.4]. 
  
Disturbed level of consciousness was found in 10 patients who were 
positive for the test compared to 20 who were negative for the test. Speech 
disturbance in 14 positive and 47 negative patients. CN affection in 18 
positive patients & 37 of the negative group motor weakness in 7 who were 
positive and 11 who were negative for the test. This is statistically non 
significant [P= 0.4]. [Fig. 4] 
Motor weakness of grade 0/5 was found in 24.0% of positive APLA 
compared to 23.6% of the negative ones. The highest percentage of the 
grades of motor weakness in APLA positive patients was found in power 
grade 2/5 and 3/5. This is statistically non significant [P= 0.43]. [Table 4] 
Abnormal blood counts (increased ESR, decreased platelets) were found 
in about 61.3% of APLA positive patients compared to 41.4% of the 
negative group. Normal blood counts was observed in 58.6% of APLA 
negative patients compared to 38.7% of the positive group. This is 
statistically significant [P= 0.005] [Table 5]. 
Abnormal lipid profile was seen in 44.8 % of APLAS -ve , 12.9% of the 
positive patients . It was normal in 55.2 % of the -ve group and 87.1% of  
the +ve individuals . This difference is statistically non significant.( P= 3.6 ); 
[Table 6] 
Echocardiography was done in eight cases, three of them had had MS, 
and were APLAS -ve. One had hypertension, one had had MS,AS,one had 
had MS,MR and all were -ve for the test. One had had IHD and was +ve for 
the test. This difference is statistically non significant ( p. 0.i5 ) . [Table 7] . 
Doppler’s U/S of the carotids was performed in six patients, only four of 
them had had carotid arteries abnormalities but were –ve for the test , the 
remaining two patients had had carotid abnormalities associated with 
positive test. This difference is statistically significant ( p.0. 002 ) [Table 8]. 
  
VDRL was done in 14 patients, eight were APLAS positive and six were 
negative. The test was positive in five of the APLAS +ve and –ve in three of 
them. It was –ve in all the six patients who were APLAS –ve . this 
difference was statistically significant ( p. 0.02 )  [Table 9] . 
AntidsDNA was done in 18 patients, 12 were APLAS +ve and six were –ve 
it was found positive in only one APLAS +ve patient and –ve in all the 
remaining 17 patients. Statistically significant (P 0.03) [Table 10]. 
ANF was done in 24 patients, 14 were APLAS +ve  and 10 were -ve . the 
test  was found to be positive in four APLAS +ve patients, one APLAS -ve 
patient. And it was -ve in the remaining 19 patients .  [Table 11] 
PTT was done n 16 patients and it was found to be abnormal in five 
patients who were APLA negative, it was normal in seven patients with 
positive APLA  and in two who were negative for the test .This is statistical 
non significant (P= 0.08) [Table 12]. 
89 of our  patients with IBD were examined by CT scan. It showed a 
single cerebral infarct in 26 patients with APLA (86.7%)and multi infarct 
brain disease in 4(13.3%).In 58 patients with a negative APLA ,53 had 
single cerebral infarcts (91.4%) and 5 had multiple infarcts (8.6%) this 
difference was not significant (P=0.4). CT brain documented cerebral 
infarction in about 32.9%of APLA positive patients and showed multi 
infarct brain disease in about 32.9% of APLA positive group. This is 
statistically non significant (P= 0.4) [Table 13]. 
  86.5% of patients with IBD stayed in hospital for more than two 
weeks. [Fig. 5]  
Different regimens were  provided to patients with IBD .Anti platelets 
alone were given in 55.1%, anti coagulants in 5.6% and anti platelets plus 
neuroprotecives  in 20.2%. [Fig. 6] 
  
On reassessing patients with IBD, a month following their stroke, 41.9% 
of APLA positive patients were unable to walk compared to 58.1% who 
were negative for the test. 16.1 % of APLA positive patients were able to 
walk with support and 41.9%  of them were  able to walk unsupported. This 
is statistically non significant.(P= 0.1). [Table 14] 
Follow up CT scan brain was done in 4 APLA positive patients and it  
was found to be normal  in only one patient . [Fig. 7] 
Table [15] demonstrated the co relation between different system 
affection and APLA in the diseased control group. The highest percentage of 
positive APLAs was found in diseases affecting the respiratory system 
(38.5%), 36.4% GIT and 28.6% affecting other systems. This is statistically 
non significant (P= 0.6). 
          
 
 
 
 
 
 
 
 
 
 
 
  
 
Table (1):  
Showing percentage of APLAS among the study population  
Group Antiphospolipid 
antibodies IBD Diseased control Healthy control
Normal -ve 58 (65.2%) 24 (68.6%) 30 (83.3%) 
Abnormal +ve 31 (34.8%) 11 (31.4%) 6 (16.7%) 
Total 89 (100%) 35 (100%) 36 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table (2):  
Showing sex distribution in the study population and APLA status 
Antiphospolipid antibodies Group  
-ve +ve 
IBD   
* Male 29 (71%) 12 (29%) 
* Female 29 (60%) 19 (40%) 
Disease control   
* Male 14 (64%) 8 (36%) 
* Female 10 (77%) 3 (23%) 
Healthy control   
* Male 14 (77%) 4 (23%) 
* Female 16 (88%) 2 (12%) 
 
 
 
 
 
 
  
 
Table (3a):  
Showing age distribution among patients presenting with IBD and 
APLA status 
Antiphospolipid antibodies IBD 
-ve +ve 
20 – 29 4 (29%) 10 (71%) 
30 – 39 5 (62%) 3 (38%) 
40 – 49 13 (76%) 4 (24%) 
50 – 59 11 (69%) 5 (31%) 
>60 25 (74%) 9 (26%) 
Total 58 (100%) 31 (100%) 
 
 
 
 
 
 
 
 
  
 
 
Table (3b):  
Showing age distribution among the disease control group and APLA 
status 
Antiphospolipid antibodies Disease control 
-ve +ve 
20 – 29 5 (63%) 3 (37%) 
30 – 39 5 (71%) 2 (29%) 
40 – 49 1 (33%) 2 (67%) 
50 – 59 4 (57%) 7 (43%) 
>60 9 (90%) 1 (10%) 
Total 24 (100%) 11 (100%) 
 
 
 
 
 
 
 
  
 
 
Table (3c):  
Showing age distribution among healthy control and APLA status 
Antiphospolipid antibodies Healthy control  
-ve +ve 
20 – 29 14 (87%) 2 (13%) 
30 – 39 12 (86%) 2 (14%) 
40 – 49 2 (67%) 1 (33%) 
50 – 59 1 (50%) 1 (50%) 
>60 1 (50%) 0 
Total 30 (100%) 6 (100%) 
 
 
 
 
 
 
 
 
  
 
 
Table (4): 
Showing the grades of motor weakness among patients with IBD and 
anti PLA status 
Antiphospolipid antibodies The grades of motor 
weakness  -ve +ve 
0/5 13 (23.6%) 6 (24.0%) 
1/5 1 (1.8%) 1 (4.0%) 
2/5 10 (18.2%) 7 (28.0%) 
3/5 27 (49.1%) 8 (32.0%) 
4/5 3 (5.5%) 3 (12.0%) 
5/5 1 (1.8%) 0 
Total  55 (100%) 25 (100%) 
 
 
 
 
 
 
  
 
 
Table (5): 
Showing FBC distribution among patients with IBD and APLAS status 
Antiphospolipid antibodies FBC 
Normal -ve Abnormal +ve 
Normal  34 (58.6%) 12 (38.7%) 
Abnormal  24 (41.4%) 19 (61.3%) 
Total  58 (100%) 31 (100%) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table (6): 
Showing lipid profile distribution among patients presenting with IBD 
and APLAS status 
Antiphospolipid antibodies Lipid profile  
Normal -ve Abnormal +ve 
Normal  32 (55.2%) 27 (87.1%) 
Abnormal  26 (44.8%) 4 (12.9%) 
Total  58 (100%) 31 (100%) 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table (7): 
Showing Echocardiographic findings in patients with IBD and APLAS 
status 
Antiphospolipid antibodies Echocardiographic 
Findings Normal -ve Abnormal +ve 
MS 3 (50.0%) 0 
AS, MR 0 1 (50.0%) 
HTN 1 (16.7%) 0 
MS, AS 1 (16.7%) 0 
MS, MR 1 (16.7%) 0 
IHD 0 1 (50.0%) 
Total  6 (100%) 2 (100%) 
 
 
 
 
 
 
  
 
 
 
Table (8): 
Showing distribution of Doppler’s carotid findings among patients with 
IBD and APLAS status 
Antiphospolipid antibodies Doppler carotids 
abnormality  Normal -ve Abnormal +ve 
Bilateral atheroma 1 (25.0%) 0 
ICA Throm 1 (25.0%) 0 
Stenosis mimial 1 (25.0%) 2 (100%) 
Proxim ICA stenosis 1 (25.0%) 0 
Total  4 (100%) 2 (100%) 
 
 
 
 
 
 
 
  
 
 
 
Table (9): 
Showing distribution of VDRL test among patients with IBD and 
APLAS status 
Antiphospolipid antibodies VDRL 
-ve +ve 
Normal 6 (100%) 3 (37.5%) 
Abnormal 0 5 (62.5%) 
Total  6 (100%) 8 (100%) 
 
 
 
 
 
 
 
 
 
  
 
 
Table (10): 
Showing distribution of antidsDNA results among patients presenting 
with IBD and APLAS status 
Antiphospolipid antibodies AntidsDNA 
-ve +ve 
Normal 6 (100%) 11 (91.7%) 
Abnormal 0 1 (8.3%) 
Total  6 (100%) 12 (100%) 
 
 
 
 
 
 
 
 
 
 
  
 
Table (11): 
Showing distribution of ANF results among patients with IBD and 
APLAS status  
Antiphospolipid antibodies ANF 
-ve +ve 
Normal       9 (90.0%) 10 (71.4%) 
Abnormal   1 (10.0%) 4 (28.6%) 
Total  10 (100%) 14 (100%) 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table (12): 
Showing distribution of PTT results among patients presenting with 
IBD and APLAS status 
Antiphospolipid antibodies PTT 
-ve +ve 
Normal 2 (50.0%) 7 (58.3%) 
Abnormal 2 (50.0%) 5 (41.7%) 
Total  4 (100%) 12 (100%) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table (13): 
Showing distribution of the final diagnosis in patients presenting with 
IBD and APLAS status 
Antiphospolipid antibodies Final diagnosis 
Normal Abnormal 
Cerebral infarct  53 (91.4%) 26 (86.7%) 
Multi-infract brain disease  5 (8.6%) 4 (13.3%) 
Total  58 (100%) 30 (100%) 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table (14): 
Showing the distribution of the degree of disability after a month in 
patients with IBD and APLA status  
Antiphospolipid antibodies Motor weakness 
Normal -ve Abnormal +ve 
Unable to walk  18 (31.0%) 13 (41.9%) 
Walk with support  20 (34.5%) 5 (16.1%) 
Walk without support 20 (34.5%) 13 (41.9%) 
Total  58 (100%) 31 (100%) 
 
 
 
 
 
 
 
 
 
  
 
Table (15):  
Showing the distribution of system affection in the disease control group 
Antiphospolipid antibodies Disease  
-ve +ve 
Chest    
* Pulm. Koch 3 5 
* Pneumonia 5 0 
GIT   
* Hepatitis  5 1 
* HCC 0 1 
* Abd. T.B 1 0 
* Belharsias  1 2 
* Brucellosis 1 0 
GUS   
* UTI 1 1 
* CRF 2 0 
CTD   
* Scleroderma  1 0 
* Overlap syn 1 0 
NS   
* GBS 1 0 
* MS 1 0 
* Malaria 0 1 
* HIV 1 0 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
 
Our study showed that 34.8% of patients suffering from IBD, 31.4% 
of the disease control and 16.7% of the healthy individuals were found to be 
APLA positive. The incidence of APLAS in patients with IBD and those 
with other diseases are comparable. This may reflect a similar pathogenesis 
of APLAS in both  groups. The incidence of APLAS in patients with IBD is 
double that in healthy individuals.  This may reflect apossible causal 
relationship between IBD and APLAS. In many studies APLAS is 
associated with increased risk for incidence and recurrence of cerebral 
ischemia , myocardial infarction and venous thrombosis .This incidence of 
positive APLA in our study group with IBD is very high compared to 
previous studies .The Barcelona study in 1991, reported an incidence of  
only 6.8% in 146 patients with IBD. 24 Another study in Milan, Italy in 1998 
reported an 18 % incidence in 55 patients with IBD. Both these studies are 
old, done 14 and seven years ago and both were done in Caucasians .Our 
result may represent a high incidence of APLA in IBD in Africans. No other 
African study is available for comparison .The higher incidence might 
partially reflect the recent availability of more sensitive assays for APLAs . 
Malaria is known to be associated with false +ve APLAS tests and the local 
high endemicity of malaria might also be contributory. The 16.7% incidence 
of +ve APLA in healthy individuals is relatively high in our study compared 
to the previous reports of five percent. Similar high percentages have been 
reported in other studies. A study conducted in normal blood donors 9 
showed high prevalence of positive test among this group. Also APLA were 
noted with certain infections and with the administration of certain drugs 11. 
  
Our results demonstrated a higher percentage of +ve APLA in IBD patients 
among females (40%) compared to males (29%) .This is closely  matched 
with a study done in New York which showed a female to male ratio of 2:1 . 
Another study in Italy showed a significant increased frequency in females. 
A third study conducted in San Antonio20 stated that APLA are an 
independent risk factor in stroke in young women .This does not match with 
the Barcelona study24 which showed males predominance in APL +ve 
patients. 
We studied 160 individuals, half of them males and the other half 
were females .24 of the males were APLA +ve  and 25 females were +ve.  
This gives an overall F:M of +ve APLA of about 1:1. 
Among IBD patients females who were  +ve for APLAs outnumber 
males with a ratio of 2:1.5 . This is in sharp contrast to the ratio in other 
diseases and in healthy individuals, where males take the lead reversing the 
ratio to 2:3 and 1:2 respectively. Taking into account the high incidence of 
APLAs in stroke patients who were in the third decade (71 %  in our study) 
the above ratios reflect that young females who are APL +ve are at a special 
high risk to develop stroke.  
In this study, the highest percentage of positive APLAs in stroke 
patients was found in the age group (20-29) that is (32.3%). This was well 
matched with a study done in San Carlo (19) which demonstrated high 
prevalence of APLA in young adults with cerebral ischemia of undetermined 
cause. Also this matches with the results of another study done in Italy with 
the same conclusion. Regarding the disease control group in our study the 
highest percentage of APLAs was found among those aged 40 – 49 (67%) 
and in the healthy control, the highest percentage was found between                 
50 – 59 (50%) .The results points to the strong association of APLA with 
  
stroke in young age .In other diseases and in healthy individuals, the 
incidence of APLA increases with age. The same observation was reported 
previously .A group of Canadian workers reported 25 % incidence of 
APLAs in patients with stroke under 45 years of age in 1998.23 
Motor weakness was the commonest presenting symptom in our 
patients with IBD regardless of the APLA status. Headache and fits were 
more common in APLA +ve patients .The incidence in the APLA positive 
group were 48% and 35 % compared to 28 % and 8.6 % in APLA –ve 
patients. This difference between the two groups was statistically significant 
(P= .004,.0001).On  the other hand disturbance of speech and consciousness 
were lower in the APLA +ve group .The incidence was 29% and 13 % 
compared to 53 % and 33 % in the APLA  -ve group .This difference was 
also statistically significant (P= 0.3 , 0.001). 
History of DVT, abortion and migraine was observed in higher 
percentage in APLA +ve patients (Fig.4). This matches with the literature, 
which stated that APLA can be detected in approximately 10 % of all 
patients with venous thrombosis. APLA also occurs with increased 
frequency (5—10%) in women with greater than three spontaneous  
recurrent abortion. A study in Austria22 showed great association between 
migraine and APS. 
Nervous system examination in our study showed cranial nerves affection in 
18 patients, speech disturbance in 14 patient, disturbed level of 
consciousness in 10 patients, motor weakness in seven patients, sensory and 
cerebellar sings were detected in three patients, optic neruritis and 
intrernuclear  ophthalmoplegia  in only one patient .This relative incidence 
of  neurological deficit is in keeping with the work reported in Iran31. 
Although stroke patient who were APLA +ve tend to have less motor 
  
weakness than those who were negative, our study showed that APLA status 
did not affect the degree of motor  weakness following stroke. Patients who 
were APLA +ve had comparable incidences of different degrees of muscle 
power to those who were APLA –ve. 
Our study showed an elevated   ESR & low platelets  in 61.3% of 
APLAS +ve patients , compared to  41.4% of the –ve group . This was 
matched with the Iran study 31 which demonstrated an elevated ESR and 
thrombocytopenia in a similar percentage of their patients. It was also in 
keeping with two other studies conducted in Boston and Douglas. Both 
concluded an association between high ESR, low platelets and APS 36. High 
ESR and low platelets can be taken as pointers to a possible +ve APLA test 
in stroke patients.  
Elevated lipid profile was found in 12.9 % of APLAS +ve patients 
compared to 44.8 % of the -ve group. It can thus be concluded that 
hyperlipidaemia plays a little role in APLAS +ve patients, although it is a 
major risk factor for stroke in general.  
Echocardiography was done in eight patients, only one patient with 
APLAS was found to have valvular lesions. This was compairable to study 
conducted in San carlo 34 which demonstrated normal echocardiographic 
findings in patients with +ve APLAS. But our findings stand in sharp 
contrast with another study published in SMJ 20 which showed an association 
between valvular lesions on echocardiography and APS. 
Atrial fibrillation was detected in four of our patients, conforming  
with a study published in American heart association 34. It stated that, 
cerebral infarction in patients with atrial fibrillation is persumed to result 
from embolization of intracardiac thrombi, commonly from the left atrium.  
  
Dopplers u/s of the carotid arteries was done in six patients of the study 
population, two patients who were APLAS +ve had had carotid stenosis  as 
well. This was matched with a study done in San carlo, that demonstrated 
significant carotid stenosis associated with positive APLAS.    
VDRL Test for syphilis was done in 14 patients and found to be 
positive in five patients with positive APLAS. This was supported by a 
study published by persons in Scotland 38 which showed an association 
between positive APLAS & false positive VDRL .  
AntidsDNA was done in a total of 18 of our patients. It was found to 
be positive in one patient out of 12 who were APLAS +ve. This is a 8.3%. In 
contrast ANF was done in 24 patients, and was found to be positive in four 
out of 14 patients who were  APLAS +ve at a percentage of 28.6 %. This 
was in keeping  with the literature which stated a significant association 
between the presence of ANF, AntidsDNA, and antiphospholipid antibodies. 
The patient who was APLAS +ve and had AntidsDNA antibodies probably 
has SLE. But most of our patient has primary APS, not associated with SLE. 
Partial Thromboplastin Time (PTT) was done in 16 patients with IBD 
and was found to be prolonged in five out of eight patients who were APLA 
+ve. This is matching with the literature 35, which showed significant 
association between a prolonged PTT and the presence of APLAs in the 
serum. 
Both cerebral infarcts and multi-infarct brain disease is demonstrated 
in our study population with ischemic brain disease. This comparable with  
to the literature which stated that both are known to occur in APS. 
In our study, IBD patients stayed in hospital for more than 2 weeks in 
86.5% of the cases, this is a considerable long hospital stay. Most of these 
patients were managed in general medical ward, a unified management 
  
scheme is lacking and a staff specially trained in stroke management is not 
available. 
Modalities of treatment provided to IBD patient was found to be as 
follows in our patients: antiplatlets alone in 55.1 % anticoagulant in 16.9 %, 
antiplatlets + anticoagulants in 5.6%,and antiplatlets + neuroprotectives in 
20.2%. This shows that only 22.5%of our IBD patients received 
anticoagulation. This was against the recommendation worldwide, that 
APLA +ve patients should all receive anticoagulation. The above-mentioned 
treatment modalities depended mainly on the preference of the treating 
physicians. These patients were not admitted in a specialized stroke unit. 
Follow up CT brain 6 weeks following stroke was performed in 4 
patients who were APLA +ve and was found to become normal in three of 
them but still abnormal in only one patient. Although this number is small 
for any sound deductions, this may indicate that APLAS imparts a special 
good prognosis to the long-term morbidity in stroke patients. 
In the diseased control group in our study, APLAS were found to be 
positive in five patients with pulmonary koch, two with bilharsiasis, one 
with hepatitis, one with hepatocellular  carcinoma, one with urinary tract 
infection and one with malaria. This was in keeping with the literature 11 in 
which APLAS were reported to be associated with similar conditions. 
 
 
 
 
 
 
  
  
CONCLUSIONS 
 
• We demonstrated a higher incidence of APLA in Sudanese patients 
than reported worldwide. 
• The female to male ratio of the APLA was 1.5 : 1 in IBD while it was 
1 : 2 in healthy controls.  
• APLAs tend to occur with higher incidence in young female stroke 
patients in keeping with the reports from other countries. 
• Stroke patients who are APLA +ve tend to have more headaches and 
fits at presentation, but they tend to have less disturbance of 
consciousness and speech, and motor weakness. 
• Follow up CT done in a small number of our APLA +ve stroke 
patients, suggests a possible long-term good prognosis in this group. 
• Strokes in APLA +ve  patients tend to be associated with history of 
DVT, abortion, and migraine, comparable with reports from other 
parts of the world. 
• In keeping with studies from other countries, APLAs in our patients  
tend to be associated with high ESR, Low platelets count, prolonged 
PTT, and carotid stenosis demonstrated by doppler U/S scanning . 
• APLAs showed strong association with +ve VDRL & ANF. 
• Modalities of treatments applied in IBD Patients lacked a unified 
treatment regimens for APLAs +ve patients with stroke.    
 
 
 
  
RECOMMENDATIONS 
 
• More research is needed into the APLA status in the general 
population in Sudan, because of the local endemicity of many 
infections known to be associated with a positive test. Our study 
suggested the local incidence to be double that reported in Europe in 
healthy individuals.    
• Healthy controls who were +ve for APLAs needs to be followed-up 
further. 
• There is a need for a more refined sensitive and specific test for 
APLA.  
• Because of the high incidence of +ve APLA in IBD patients, this test 
should be included among the routine investigations of stroke patients, 
specially young females without evident other risk factors. 
• IBD patients who present with headache and fits, specially if they 
report migraine, DVT, or abortion in the past history, need to be 
investigated for APLA. 
• A high ESR and low platelet count can be taken as pointers to                 
a possible +ve APLA test.   
• Anti phospholipid syndrome should be suspected in any patient with 
the disease who has a +ve VDRL, ANF test or prolonged PTT.  
• It is time to establish a specialized stroke units and set a unified 
regimen of treatments for those patients. In order to improve the 
outcome and prognosis. 
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